Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult

January 2013
International Journal of Hematology & Oncology / UHOD: Uluslarar;2013 Supplement, Vol. 23 Issue 1, p1
Academic Journal
A letter to the editor is presented regarding the use of tyrosine kinase inhibitor (TKI) in the management of chronic myeloid leukemia (CML) is presented.


Related Articles

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Dec2012 Pharmacology Watch, p2 

    The article offers information on a drug approved by the U.S. Food and Drug Administratioin (FDA) for treating chronic myelogenous leukemia (CML) with the tyrosine kinase inhibitors (TKIs) therapy such as perampanel for patients with partial onset seizures.

  • Nilotinib vs dasatinib - nilotinib wins for CML in the real world.  // PharmacoEconomics & Outcomes News;1/22/2011, Issue 620, p6 

    The article discusses research which compared the adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia, referencing a study by A. Guerin and colleagues published in the 52nd Annual Meeting and Exposition of the American Society of Hematology.

  • Cancer: Next-generation CML therapy. Aranda, Victoria // Nature Medicine;Jan2013, Vol. 19 Issue 1, p28 

    The article focuses on a research which found that a novel BCR-ABL inhibitor can be used for treating patients with chronic myeloid leukemia (CML).

  • TKIs and the treatment of CML in pregnant women. Sweany, Starla J. // Hem/Onc Today;10/25/2011, Vol. 12 Issue 20, p26 

    The article discusses the effect of tyrosine kinase inhibitors, such as imatinib, on pregnant women for the treatment of chronic myeloid leukemia and suggests strategies to manage the disease in these women.

  • Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Brownlow, N; Vaid, M; Dibb, N J // Leukemia (08876924);Jul2008, Vol. 22 Issue 7, p1452 

    This article discusses research into the use of the quinazoline-based tyrosine kinase inhibitor tandutinib to treat acute myeloid leukemia. The drug, which targets the Flt-3 receptor, was found to inhibit the FMS receptors of macrophage-colony stimulating factor and osteoclastogenesis in vitro....

  • The Accelerated Approval of Oncologic Drugs. Prasad, Vinay; Mailankody, Sham // JAMA: Journal of the American Medical Association;1/22/2014, Vol. 311 Issue 4, p353 

    The authors discuss the lessons learned on the accelerated approval of the BCR-ABL tyrosine kinase inhibitor ponatinib for the treatment of chronic myeloid leukemia (CML). They note that ponatinib illustrates core tension inherent in the Accelerated Approval program. They state that the drug...

  • Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. El Missiry, Mohamed; Hjorth-Hansen, Henrik; Richter, Johan; Olson-Strömberg, Ulla; Stenke, Leif; Porkka, Kimmo; Kreutzman, Anna; Mustjoki, Satu // PLoS ONE;1/30/2017, Vol. 12 Issue 1, p1 

    In chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of tyrosine kinase inhibitor (TKI) treatment to predict therapy response....

  • Systematic review of dasatinib in chronic myeloid leukemia. Breccia, Massimo; Salaroli, Adriano; Molica, Matteo; Alimena, Giuliana // OncoTargets & Therapy;2013, Vol. 6, p257 

    Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase...

  • Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs. Breccia, Massimo; Alimena, Giuliana // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    With the advent of target therapies, imatinib became the mainstay for treatment of chronic myeloid leukemia. However, despite the brilliant results obtained with this drug, more than 30% of patients discontinue therapy in long-term due to several reasons, including failure and/or intolerance....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics